tbuckley/cabot-search huggingface dataset:
Circular RNA ciRS-7—A Promising Prognostic Biomarker and a Potential Therapeutic Target in Colorectal Cancer
Authors: Wenhao Weng, Qing Wei, Shusuke Toden, Kazuhiro Yoshida, Takeshi Nagasaka, Toshiyoshi Fujiwara, Sanjun Cai, Huanlong Qin, Yanlei Ma, Ajay Goel
Journal: Clinical Cancer Research (2017)

Purpose: Colorectal cancer is one of the most common malignancies worldwide. Recently, a novel circular RNA, ciRS-7, was proposed to be a potential miR-7 sponge. As miR-7, a putative tumor-suppressor, regulates the expression of several important drivers of colorectal cancer, we analyzed the clinical significance of ciRS-7 in colorectal cancer patients.Experimental Design: Initially, we evaluated the expression levels of ciRS-7 in a training cohort comprising of 153 primary colorectal cancer tissues and 44 matched normal mucosae. We subsequently confirmed its clinical relevance in an independent validation cohort (n = 165), and evaluated the effect of ciRS-7 on miR-7, and its target genes EGFR and RAF1. Functional analyses were performed in cell lines and an animal model to support clinical findings.Results: Our data revealed that ciRS-7 was significantly upregulated in colorectal cancer tissues compared with matched normal mucosae (P = 0.0018), and its overexpression was associated with poor patient survival (P = 0.0224 and 0.0061 in the training and validation cohorts, respectively). Multivariate survival analysis revealed that ciRS-7 emerged as an independent risk factor for overall survival (P = 0.0656 and 0.0324 in the training and validation cohorts, respectively). Overexpression of ciRS-7 in HCT116 and HT29 cells led to the blocking of miR-7 and resulted in a more aggressive oncogenic phenotype, and ciRS-7 overexpression permitted the inhibition of miR-7 and subsequent activation of EGFR and RAF1 oncogenes.Conclusions: CiRS-7 is a promising prognostic biomarker in colorectal cancer patients and may serve as a therapeutic target for reducing EGFR-RAF1 activity in colorectal cancer patients. Clin Cancer Res; 23(14); 3918-28. ©2017 AACR.
Forewarned Is Forearmed- Comparison of Southern Network on Adverse Reactions (SONAR) Versus an FDA-Mandated Prospective Observational Registry Assessment of Gemtuzumab Ozogamycin-Associated Sinusoidal Obstructive Syndrome
Authors: Jametta Magwood, Peter Georgantopoulos, LeAnn B Norris, Charles L. Bennett
Journal: Blood (2014)
Comparison of Gel Versus Capillary Electrophoresis for Chimerism Monitoring by PCR Amplification of Microsatellite Markers after Allogeneic Hematopoietic Cell Transplantation.
Authors: Robert Zeiser, Alexandros Spyridonidis, Ralph Waesch, Hartmut Bertz, Jurgen Finke
Journal: Blood (2004)
The IPI Predicts Outcome in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with Immunochemotherapy: A Report of the University of Iowa/Mayo Clinic SPORE
Authors: Thomas M. Habermann, B.K. Link, M.J. Maurer, J.E. Wooldridge, S.M. Geyer, W.R. Macon, C. Allmer, S.M. Ansell, T.E. Witzig, G.J. Weiner, J.R. Cerhan
Journal: Blood (2007)
Unmanipulated Haploidentical Hematopoietic Stem Cell Transplantation Might Overcome the Adverse Effect of Minimal Residue Disease Pretransplant in Patients with Standard-Risk Acute Myeloid Leukemia
Authors: Xiaosu Zhao, Yazhen Qin, Yanrong Liu, Lanping Xu, Xiao-Hui Zhang, Xiaojun Huang, Yingjun Chang
Journal: Blood (2015)
Clincial Evidence That Very Small Embryonic Like (VSEL) Stem Cells Are Mobilizaed into Peripheral Blood in Patents after Stroke.
Authors: Magda Kucia, Edyta Paczkowska, Dorota Koziarska, Maciej Halasa, Krzysztof Safranow, Anna Karbicka, Marta Nowik, Przemyslaw Nowacki, Mariusz Z. Ratajczak, Boguslaw Machalinski
Journal: Blood (2007)
Childhood Lung Function Predicts Adult Chronic Obstructive Pulmonary Disease and Asthma–Chronic Obstructive Pulmonary Disease Overlap Syndrome
Authors: Dinh S. Bui, John A. Burgess, Adrian J. Lowe, Jennifer L. Perret, Caroline J. Lodge, Minh Bui, Stephen Morrison, Bruce R. Thompson, Paul S. Thomas, Graham G. Giles, Judith Garcia-Aymerich, Debbie Jarvis, Michael J. Abramson, E. Haydn Walters, Melanie C. Matheson, Shyamali C. Dharmage
Journal: American Journal of Respiratory and Critical Care Medicine (2017)

Rationale: The burden of chronic obstructive pulmonary disease (COPD) is increasing, yet there are limited data on early life risk factors.Objectives: To investigate the role of childhood lung function in adult COPD phenotypes.Methods: Prebronchodilator spirometry was performed for a cohort of 7-year-old Tasmanian children (n = 8,583) in 1968 who were resurveyed at 45 years, and a selected subsample (n = 1,389) underwent prebronchodilator and post-bronchodilator spirometry. For this analysis, COPD was spirometrically defined as a post-bronchodilator FEV1/FVC less than the lower limit of normal. Asthma–COPD overlap syndrome (ACOS) was defined as the coexistence of both COPD and current asthma. Associations between childhood lung function and asthma/COPD/ACOS were examined using multinomial regression.Measurements and Main Results: At 45 years, 959 participants had neither current asthma nor COPD (unaffected), 269 had current asthma alone, 59 had COPD alone, and 68 had ACOS. The reweighted prevalence of asthma alone was 13.5%, COPD alone 4.1%, and ACOS 2.9%. The lowest quartile of FEV1 at 7 years was associated with ACOS (odds ratio, 2.93; 95% confidence interval, 1.32–6.52), but not COPD or asthma alone. The lowest quartile of FEV1/FVC ratio at 7 years was associated with ACOS (odds ratio, 16.3; 95% confidence interval, 4.7–55.9) and COPD (odds ratio, 5.76; 95% confidence interval, 1.9–17.4), but not asthma alone.Conclusions: Being in the lowest quartile for lung function at age 7 may have long-term consequences for the development of COPD and ACOS by middle age. Screening of lung function in school age children may identify a high-risk group that could be targeted for intervention. Further research is needed to understand possible modifiers of these associations and develop interventions for children with impaired lung function.
Non-Myeloablative Hematopoietic Stem Cell Transplantation in Older Patients with AML and MDS: Results from the Center for International Blood and Marrow Transplant Research (CIBMTR)
Authors: Brian McClune, Daniel J. Weisdorf, John F. DiPersio, Armand Keating, Tanya L. Pedersen, Gisela Tunes da Silva, J. Sierra, Martin S. Tallman, Sergio A. Giralt
Journal: Blood (2008)
Neuronal CTGF/CCN2 negatively regulates myelination in a mouse model of tuberous sclerosis complex
Authors: Ebru Ercan, Juliette M. Han, Alessia Di Nardo, Kellen Winden, Min-Joon Han, Leonie Hoyo, Afshin Saffari, Andrew Leask, Daniel H. Geschwind, Mustafa Sahin
Journal: The Journal of Experimental Medicine (2017)

Disruption of myelination during development has been implicated in a range of neurodevelopmental disorders including tuberous sclerosis complex (TSC). TSC patients with autism display impairments in white matter integrity. Similarly, mice lacking neuronal Tsc1 have a hypomyelination phenotype. However, the mechanisms that underlie these phenotypes remain unknown. In this study, we demonstrate that neuronal TSC1/2 orchestrates a program of oligodendrocyte maturation through the regulated secretion of connective tissue growth factor (CTGF). We characterize oligodendrocyte maturation both in vitro and in vivo. We find that neuron-specific Tsc1 deletion results in an increase in CTGF secretion that non-cell autonomously stunts oligodendrocyte development and decreases the total number of oligodendrocytes. Genetic deletion of CTGF from neurons, in turn, mitigates the TSC-dependent hypomyelination phenotype. These results show that the mechanistic target of rapamycin (mTOR) pathway in neurons regulates CTGF production and secretion, revealing a paracrine mechanism by which neuronal signaling regulates oligodendrocyte maturation and myelination in TSC. This study highlights the role of mTOR-dependent signaling between neuronal and nonneuronal cells in the regulation of myelin and identifies an additional therapeutic avenue for this disease.
Efficacy and Safety of Peroral Endoscopic Myotomy for Treatment of Achalasia After Failed Heller Myotomy
Authors: Saowanee Ngamruengphong, Haruhiro Inoue, Michael B. Ujiki, Lava Y. Patel, Amol Bapaye, Pankaj N. Desai, Shivangi Dorwat, Jun Nakamura, Yoshitaka Hata, Valerio Balassone, Manabu Onimaru, Thierry Ponchon, Mathieu Pioche, Sabine Roman, Jérôme Rivory, François Mion, Aurélien Garros, Peter V. Draganov, Yaseen Perbtani, Ali Abbas, Davinderbir Pannu, Dennis Yang, Silvana Perretta, John Romanelli, David Desilets, Bu Hayee, Amyn Haji, Gulara Hajiyeva, Amr Ismail, Yen-I Chen, Majidah Bukhari, Yamile Haito-Chavez, Vivek Kumbhari, Payal Saxena, Michael Talbot, Philip Wai-yan Chiu, Hon-Chi Yip, Vivien Wai-Yin Wong, Ruben Hernaez, Roberta Maselli, Alessandro Repici, Mouen A. Khashab
Journal: Clinical Gastroenterology and Hepatology (2017)
Results of a Randomized Phase 2 Study of Clofarabine Plus Cytarabine (CA) Vs Clofarabine Plus Idarubicin (CI) Vs Clofarabine, Idarubicin, Plus Cytarabine (CIA) as Salvage Therapy in Acute Myeloid Leukemia (AML).
Authors: Stefan Faderl, Gautam Borthakur, Farhad Ravandi, Xuelin Huang, Miloslav Beran, Alessandra Ferrajoli, Charles A. Koller, Deborah A. Thomas, Srdan Verstovsek, Monica Kwari, Hagop M. Kantarjian
Journal: Blood (2008)
Role of JAK 2 Mutation Detection in Budd-Chiari Syndrome (BCS) and Portal Vein Thrombosis (PVT) Associated to MPD.
Authors: Jean-Jacques Kiladjian, Francisco Cervantes, Frank W.G. Leebeek, Sylvie Chevret, Dominique Cazals-Hatem, Aurélie Plessier, Christophe Marzac, Bruno Cassinat, Sebastian Raffa, Juan Carlos Garcia-Pagan, Sarwa Darwish Murad, Harry L.A. Janssen, Dominique Valla, Nicole Casadevall, Pierre Fenaux
Journal: Blood (2006)
Use of diagnostic testing for patients with early-stage breast cancer in a multi-hospital quality collaborative in Michigan.
Authors: Tara M. Breslin, James Kubus, Haythem Y. Ali, T. Trevor Singh, Paul T. Adams, Angela Applewhite, Ann M. Mehringer, Samuel M. Silver
Journal: Journal of Clinical Oncology (2012)

242 Background: In 2012, ASCO identified five opportunities to improve the quality of cancer care and reduce costs. Two of these recommendations focused on limiting use of advanced diagnostic imaging with computed tomography (CT), Positron Emission Tomography (PET), and radionuclide bone scans (BS) at diagnosis and during surveillance for women with early stage breast cancer with a low risk of metastasis. We describe the use of diagnostic imaging among patients with early stage breast cancer treated at hospitals in Michigan. Methods: The Michigan Breast Oncology Quality Initiative is a collaboration between Michigan hospitals, the University of Michigan Comprehensive Cancer Center, and the National Comprehensive Cancer Network (NCCN). This collaborative collects longitudinal demographic, staging, treatment, and follow up data using the NCCN Breast Outcomes Database platform. We analyzed use of advanced diagnostic testing with CT, PET, BS and contrast it with use of traditional imaging (mammography/ultrasound) at diagnosis and during follow up in patients with stage 0, I, II breast cancer between 1998 to 2009. Patients who died or recurred were excluded. Results: The cohort included 7,632 patients (19.6% stage 0, 48.1% stage I, 32.3% stage II) treated at 17 hospitals. Use of traditional imaging was documented in nearly 100% of patients at diagnosis and throughout the follow up period. With respect to advanced diagnostic imaging, 20.3 % underwent CT, 4.7% underwent PET, and 11.6% underwent BS at diagnosis. Advanced testing use decreased over time (Table). Conclusions: Despite published guidelines, which recommend against their routine use, advanced diagnostic imaging use was prevalent among patients treated for early breast cancer at MiBOQI hospitals. Education efforts should target physicians and patients on the lack of proven benefit and potential risks of using advanced diagnostic imaging in this population. [Table: see text]
Activation of Notch-Hes Signaling Pathway Impairs Osteogenic Differentiation and Hematopoietic Stem Cell-Supporting Capacitiy of Mesenchymal Stromal Cells Derived from Myelodysplastic Syndromes Patients
Authors: Chunkang Chang, Chengming Fei, Juan Guo, Youshan Zhao, Shucheng Gu, Xiao Li
Journal: Blood (2015)
The Opposing Roles of Let-7c and Mir-125-b2 in Human Hematopoietic Stem Cell Maintenance and Proliferation
Authors: Vanessa L. Bundy, Salemiz Sandoval, Christopher Seet, Chintan Parekh, Edward He, Yuhua Zhu, Lisa A. Kohn, Dinesh Rao, Gay Crooks
Journal: Journal of Allergy and Clinical Immunology (2017)
59P Characterization of PD-L1 expression in Chinese non-small cell lung cancer patients with PTEN IHC as a means for sample quality screening
Authors: X.-C. Zhang, C. Sun, Z. Xie, X. Cao, J.-J. Guo, J.-J. Yang, X.-N. Yang, H. Dai, J. Lee, Y.-X. Zuo, M. Chen, A. Kiermaier, D. Shames, G. Cheng, Y.-L. Wu
Journal: Annals of Oncology (2016)
The Impact and Safety of an Updated Anaphylaxis Clinical Pathway in a Busy Pediatric Emergency Department
Authors: Juhee Lee, Bonnie Rodio, Jane Lavelle, Megan Ott Lewis, Jennifer Molnar, Cynthia Jacobstein, Sarah Hadley, Rachel English, Lisa Zielinski, Nicholas Tsarouhas, Terri F. Brown-Whitehorn
Journal: Journal of Allergy and Clinical Immunology (2017)
Analysis of the Clinical Impact of the Use of Palifermin in Patients Undergoing Autologous Peripheral Blood Progenitor Cell Transplantation for Multiple Myeloma and Relapsed Lymphoma
Authors: Kari Kolm, Ronan Foley, Jolanta Jeziorowska, Deborah C Marcellus, Ann Benger, Michael Trus, Graeme A M Fraser, Pamela O’Hoski, Carol Ingram, Michael Ricci, Josh Kiczma, C. Tom Kouroukis
Journal: Blood (2008)
Genetic polymorphisms in DNA mismatch repair-related genes predict outcome in patients with head and neck squamous cell carcinoma treated with cisplatin and radiotherapy
Authors: G.J. Lourenço, G.A.S. Nogueira, L. Lopes-Aguiar, E.F.D. Costa, T.R.P. Lima, M.B. Visacri, E.C. Pincinato, L. Calonga, F.V. Mariano, A.M.A.M. Altemani, J.M.C. Altemani, C.M. Coutinho-Camillo, M.A.V.F.R. Alves, P. Moriel, C.T. Chone, C.D. Ramos, C.S.P. Lima
Journal: Annals of Oncology (2016)
Clinical prognostic factors associated with outcome in patients with metastatic clear-cell renal cell cancer treated with everolimus.
Authors: Robert J. Amato, Amber Flaherty, Somyata Saxena, Mika Stepankiw
Journal: Journal of Clinical Oncology (2012)

443 Background: Everolimus, an oral mammalian target of rapamycin (mTOR) inhibitor, has demonstrated efficacy affects tumor growth by blocking growth factor stimulation, arresting cell cycle progression, and inhibiting angiogenesis. mTOR inhibitors and agents with primarily antiangiogenic activity have been shown to have efficacy in renal cell cancer (RCC). This study expanded the original everolimus study of 41 patients with metastatic clear cell renal cell cancer to 66 patients to examine outcome and clinical prognostic factors associated with outcome Methods: Patients had confirmed predominantly clear cell RCC. Everolimus was given at a dose of 10 mg daily orally without interruption (28-day cycle), with dose modifications for toxicity (graded according to National Cancer Institute Common Toxicity Criteria, version 3.0). Patients were evaluated every 2 cycles (8 weeks) using Response Evaluation Criteria in Solid Tumors (RECIST). Results: Of 66 evaluable and treated patients, 73% were male, and 45% were &gt;60. Forty-five percent had right kidney involvement, 49% left kidney involvement, and 6% had dual kidney involvement. Eighty-six percent had prior systemic therapy, and 76% of patients had at least two metastatic sites including lung (72%), liver (26%), bone (48%), lymph nodes (50%), adrenal (21%), and other (39%). Twenty-four (36%) of patients had a progression-free survival (PFS) of ≥12 months, and 40 patients (61%) had an overall survival (OS) ≥12 months. Factors most likely to have an influence on OS benefit was high LDH, alkaline phosphatase, and calcium; low hemoglobin; and prior treatment with tyrokinase inhibitors. Conclusions: Everolimus was found to have clinical benefit in patients with clear cell RCC. Clinical prognostic factors may help determine patients most likely to receive benefit from everolimus. Information regarding curves and correlation between prognostic factors and OS and PFS will be presented.
Selection of the optimal dose for an ultra-short course subcutaneous immunotherapy (SCIT) for Rhinoconjunctivitis for Birch Allergic patients
Authors: Margitta Worm, Stefan Zielen, Tim Higenbottam, Oliver Pfaar, Ralph Mosges, Werner Aberer, Matthias Kramer, Murray Skinner, Bev Lees
Journal: Journal of Allergy and Clinical Immunology (2017)
Salvage Treatment with Lenalidomide and Dexamethasone in Patients with Relapsed Refractory Mantle Cell Lymphoma.
Authors: Francesco Zaja, Stefano De Luca, Umberto Vitolo, Lorella Orsucci, Alessandro Levis, Flavia Salvi, Livio Gargantini, Erika Ravelli, Alessandra Tucci, Chiara Bottelli, Monica Balzarotti, Armando Santoro, Ercole Brusamolino, Maurizio Bonfichi, Alice Di Rocco, Caterina Stelitano, Luca Baldini, Stefano Aldo Pileri, Stefano Volpetti, Giovannino Ciccone, Antonella Ferranti, Renato Fanin
Journal: Blood (2009)
Efficacy of Component Resolved Diagnosis in Walnut and Cashew Nut Allergies
Authors: Mikita Yamamoto, Sakura Sato, Takashi Inoue, Makoto Nishino, Kenichi Nagakura, Tomoyuki Asaumi, Kiyotake Ogura, Noriyuki Yanagida, Motohiro Ebisawa
Journal: Journal of Allergy and Clinical Immunology (2017)
CHOP-R + Bortezomib as Initial Therapy for Mantle Cell Lymphoma (MCL).
Authors: Jia Ruan, Peter Martin, Richard R Furman, Julie M. Vose, Ann LaCasce, Ying-Kuen K. Cheung, Jennifer O'Loughlin, Rebecca Elstrom, Ruben Niesvizky, Amy Chadburn, Scott Ely, Ethel Cesarman, Morton Coleman, John P. Leonard
Journal: Blood (2009)
Current status of FOLFIRINOX in Japan: modified or original?
Authors: Hideki Ueno, Satoshi Shiba, Mitsuhito Sasaki, Hiroshi Ishii, Masato Ozaka, Akira Fukutomi, Akiko Todaka, Masafumi Ikeda, Junji Furuse, Takuji Okusaka
Journal: Annals of Oncology (2016)
Circulating T cells, natural killer (NK) cells and group 2 innate lymphoid cells (ILC2) of severe asthmapatients from the University of California Asthma Network (UCANTM) clinic, express increased levels of both IL-13 and IL-17
Authors: Moyar Qing Ge, Daniel G. Tompkins, Maya Juarez, Erik D. Larson, Brian M. Morrissey, Nicholas J. Kenyon, Angela Haczku
Journal: Journal of Allergy and Clinical Immunology (2017)
OS2.2 Paracrine impairment of antitumor T cell immunity by IDH1-mutant gliomas
Authors: L. Bunse, T. Bunse, S. Pusch, F. Sahm, K. Sanghvi, A. Berghoff, M. Steadman, B. Niemeyer, W. Wick, M. Platten
Journal: Neuro-Oncology (2016)

response to TMZ involving different classes of RNAs, both coding and noncoding.RESULTS: We developed a pipeline to build the "RNA interactome" and revealed lncRNAs involved in regulatory circuits of GBM response to TMZ.We next inferred putative biological functions for key lncRNAs by in silico gene co-expression analysis.Interestingly, lncRNAs were mapped to processes linked to drug sensitivity, cell cycle regulation and/or developmental pathways.By exploring public datasets of The Cancer Genome Atlas (TCGA) in which part of the identified lncRNAs were annotated, we identified several TMZ-regulated lncRNAs that are correlated with patient survival.CONCLUSION: Altogether, this integrative analysis of small RNA-seq and RNA-seq data provides new RNA-based predictors of chemoresistance, as well as potential targets to counteract TMZ resistance in GBM.
Hepatocyte Growth Factor-Producing Multiple Myeloma (HGF myeloma) Is a Distinct Clinical Entity and Needs for Molecular Targeted Therapy.
Authors: Yutaka Hattori, Shin-ichiro Okamoto, Wenlin Du, Taketo Yamada, Naoki Shimada, Kunio Matsumoto, Morihiko Sagawa, Yasuo Ikeda
Journal: Blood (2008)
Characteristics and Outcomes of Patients with Lung Cancer Harboring Multiple Molecular Alterations: Results from the IFCT Study Biomarkers France
Authors: Nicolas Guibert, Fabrice Barlesi, Renaud Descourt, Hervé Léna, Benjamin Besse, Michèle Beau-Faller, Jean Mosser, Eric Pichon, Jean-Philippe Merlio, L'Houcine Ouafik, François Guichard, Bénédicte Mastroianni, Lionel Moreau, Annie Wdowik, Jean-Christophe Sabourin, Antoinette Lemoine, Pascale Missy, Alexandra Langlais, Denis Moro-Sibilot, Julien Mazières
Journal: Journal of Thoracic Oncology (2017)
Functional Significance of MPL Expression in the Human Primitive Hematopoietic Stem Cell Compartment
Authors: Masaya Takahashi, Yoshikazu Matsuoka, Ryuji Iwaki, Ryusuke Nakatsuka, Tatsuya Fujioka, Hirao Kohno, Kazuo Matsui, Hiroaki Asano, Yutaka Sasaki, Kazunari Kaneko, Yoshiaki Sonoda
Journal: Blood (2012)
Prognostic significance of immunohistochemical subtyping and PAM50 intrinsic subtypes in male breast cancer (MaBC)
Authors: M. Alvarez, A. Sanchez-Muñoz, A. Santonja, Y. Plata Fernández, J. Miramón, I. Zarcos Pedrinaci, C. Llacer, V. de Luque, M.J. Lozano León, J.M. Jerez, L. Pérez Villa, R. Lavado, C. Ramirez, A. Jiménez, I. Rodrigo, E. García, L. Vicioso, E. Alba Conejo
Journal: Annals of Oncology (2016)
Phase II trial with carboplatin/gemcitabine induction chemotherapy followed by radiotherapy concomitantly with paclitaxel/gemcitabine in stage III non-small cell lung cancer (NSCLC)
Authors: V. Hirsh, M. Duclos, L. Souhami, P. Del Vecchio, L. Ofiara, S. Faria, J. Ayoub, D. Charpentier, L. Portelance, D. Soulieres
Journal: Journal of Clinical Oncology (2006)

7139 Background: The optimal combination of concomitant thoracic radiotherapy (TRT) and CT in stage III unresectable NSCLC remains unclear. The role of induction CT with Cb/G regimen, less toxic than Cisplatin/G, has not been established in stage III NSCLC. Methods: Forty-two patients (pts), 41 evaluable, entered this trial between January 2003 and November 2004, 27 males, 14 females, median age 60 (37–70), 19 pts with ECOG PS 0, 22 pts with PS 1, 22 pts with stage III A (N 2 ), and 19 pts with stage III B (N 2 , N 3 ). They received Cb AUC 5 i.v. on day 1 and G 1000 mg/m 2 i.v. on days 1 + 8 every three weeks x 2 cycles, followed on day 50 by TRT, 60 Gy over 6 weeks, concomitantly with P 50 mg/m 2 i.v. and G 100 mg/m 2 i.v. on days 1 + 8 every three weeks x 2 cycles. Results: After induction CT, partial response (PR) was 73.1% (30 pts), stable disease (SD) 24.4% (10 pts), and 2.5% (1 pt) had progressive disease. After TRT and P/G, 19.5% (8 pts) had CR, 75.6% (31 pts) PR, and 4.9% (2 pts) PD. Median time-to-disease progression was 11.5 months. Median survival has not been reached yet, but surpassed 16.5 months; one-year survival is 71% (29 pts). Twenty three patients are still alive, after minimal follow-up of 13 months. First site of PD was in lungs in 7 pts, in brain 5 pts, in bones 4 pts; 2 pts died without PD, of cardiovascular disease. Toxicity of induction CT was minimal. During TRT and CT, grade 3 neutropenia, thrombocytopenia, and anemia occurred in 8 pts, 3 pts, and 3 pts respectively, grade 4 neutropenia and thrombocytopenia in one pt each. Nine pts received red cell transfusions, one pt platelet transfusion. One patient developed esophageal fistula with grade 4 toxicity, 3 pts had grade 3 esophagitis, 2 pts grade 3 infections, and one pt grade 3 dermatitis and elevation of liver enzymes. Conclusions: This regimen is effective, well tolerated, and appears to be an excellent choice for stage III NSCLC. Sponsored by Eli Lilly Canada. [Table: see text]
Validation of an Algorithm Identifying Incident Primary Immune Thrombocytopenia in the French National Health Insurance Database
Authors: Salim Mezaache, Hélène Derumeaux, Pierre Ferraro, Pascal Capdebon, Jean-Christophe Steinbach, Xavier Aballe, Deborah Palas, Nabil Saichi, Franck Burgan, Karine Desboeuf, Maryse Lapeyre-Mestre, Laurent Sailler, Guillaume Moulis
Journal: Blood (2016)